Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:5281969
Structure:
Synonyms:
"anandamide; anandamide(20:4, n-6); n-arachidonoyl ethanolamine"
(5Z,8Z,11Z,14Z)- N-(2-Hydroxyethyl)- 5,8,11,14-eicosatetraenamide
(5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide
(5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
(all-Z)-N-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide
5,8,11,14-eicosatetraenamide, N-(2-hydroxyethyl)-
5,8,11,14-Eicosatetraenamide, N-(2-hydroxyethyl)-, (5Z,8Z,11Z,14Z)-
5,8,11,14-Eicosatetraenamide, N-(2-hydroxyethyl)-, (all-Z)-
5,8,11,14-Eicosatetraenoylethanolamide
94421-68-8
A0580_SIGMA
AE
AEA
AIDS-342672
AIDS342672
Anandamide
Anandamide (20.4, n-6)
anandamide (20.4,n-6)
Anandamide(20:4, n-6)
Anandamide; Anandamide(20:4, n-6); N-arachidonoyl ethanolamine
AnNH
Arachidonic acid N-(hydroxyethyl)amide
Arachidonoyl ethanolamide
arachidonoyl-EA
arachidonoylethanolamide
Arachidonyl ethanolamide
Arachidonylethanolamide
BSPBio_001533
C078814
C11695
C22H37NO2
CHEBI:2700
CPD-7598
IDI1_034003
LMFA08040001
LS-63781
N-(2-Hydroxyethyl)-5,8,11,14-eicosatetraenamide (all-Z)-
N-(2-Hydroxyethyl)anachidonamide
N-(2-hydroxyethyl)arachidonamide
N-(5Z,8Z,11Z,14Z-icosatetraenoyl)-ethanolamide
N-arachidonoyl ethanolamine
N-arachidonoyl ethanolamine;
N-Arachidonoyl-2-hydroxyethylamide
n-arachidonoylethanolamide
N-Arachidonoylethanolamine
NCGC00161195-03
NCGC00161195-04
NCGC00161195-05
NCGC00161195-06
NCGC00161195-07
nchembio.129-comp2
nchembio.86-comp2
SMP2_000328
ZINC03809850
[14C]Anandamide
[3H]Anandamide

Target

show target details
Uniprot ID:LOX5_HUMAN
Synonyms:
5-lipoxygenase
5-LO
Arachidonate 5-lipoxygenase
EC-Numbers:1.13.11.34
Organism:Homo sapiens
Human
PDB IDs:2ABV
Structure:
2ABV

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

11095952
Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade.. M Maccarrone; S Salvati; M Bari; Finazzi-Agrˇ (2000) Biochemical and biophysical research communications display abstract
Treatment of intact human neuroblastoma CHP100 cells with anandamide (arachidonoylethanolamide, AEA) or 2-arachidonoylglycerol (2-AG) inhibits intracellular fatty acid amide hydrolase (FAAH). This effect was not associated with covalent modifications of FAAH, since specific inhibitors of farnesyltransferase, kinases, phosphatases, glycosyltransferase or nitric oxide synthase were ineffective. Electrophoretic analysis of (33)P-labelled proteins, Western blot with anti-phosphotyrosine antibodies, and glycan analysis of cellular proteins confirmed the absence of covalent modifications of FAAH. The inhibition by AEA was paralleled by an increased arachidonate release, which was not observed upon treatment of cells with linoleoylethanolamide, palmitoylethanolamide, or oleoylethanolamide. Moreover, cell treatment with AEA or 2-AG increased the activity of cyclooxygenase and 5-lipoxygenase, and the hydro(pero)xides generated from arachidonate by lipoxygenase were shown to inhibit FAAH, with inhibition constants in the low micromolar range. Consistently, inhibitors of 5-lipoxygenase, but not those of cyclooxygenase, significantly counteracted the inhibition of FAAH by AEA or 2-AG.